SCHEMBL1746847

SCHEMBL1746847

CCCN(Cc1ccc(C(=O)OC)cc1)c1nc(C)c(C)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 3/20 0.46
AGTR2 P50052 3/20 0.46
MAPT P10636 5/20 0.44
ALDH1A1 P00352 4/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
GAA P10253 2/20 0.44
KMT2A Q03164 2/20 0.44
RAB9A P51151 6/20 0.44
NPC1 O15118 5/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
CYP4A11 Q02928 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
AR P10275 1/20 0.40
KARS1 Q15046 1/20 0.40
NR3C1 P04150 1/20 0.40
MLYCD O95822 1/20 0.39
LPAR1 Q92633 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745726 0.85 RARA (0.53) AGTR1AGTR2MAPTALDH1A1LMNA
SCHEMBL1746924 0.78 KMT2A (0.52) MAPTALDH1A1KDM4EMEN1GAA
SCHEMBL1745417 0.76 KDM4E (0.50) AGTR1AGTR2MAPTALDH1A1LMNA
SCHEMBL1747398 0.74 PPARD (0.54) LMNAL3MBTL1
SCHEMBL1100877 0.74 GCGR (0.51) MAPTALDH1A1L3MBTL1
SCHEMBL1206463 0.73 HRH3 (0.55) MAPTALDH1A1KDM4EMEN1GAA
SCHEMBL20879369 0.71 ALDH1A1 (0.54) MAPTALDH1A1KDM4EGAANPC1
SCHEMBL8649876 0.70 MEN1 (0.51) MAPTALDH1A1LMNAKDM4EMEN1
SCHEMBL1745336 0.69 RARA (0.53) MAPTALDH1A1LMNAKDM4EMEN1
SCHEMBL1744789 0.68 KMT2A (0.54) MAPTALDH1A1KDM4EMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR AGTR1 169/4885AGTR2 241/4885MAPT 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.